Infection Prevention Equipment With Microbiome Therapeutics For Clinical Trials Applications
1 equipment items found
-
Manufactured by Finch Therapeutics Group, Inc.based in USA
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you